about
Perlecan domain IV peptide stimulates salivary gland cell assembly in vitroHeparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formationExpression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitroOsteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channelPerlecan functions in chondrogenesis: insights from in vitro and in vivo modelsSpatiotemporal distribution of heparan sulfate epitopes during murine cartilage growth plate developmentIdentification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS)-binding protein in rat IEC-6 cellsImproved cellular specificity of plasmonic nanobubbles versus nanoparticles in heterogeneous cell systems.Structure-based design of selective agonists for a rickets-associated mutant of the vitamin d receptor.Bioactive analogs that simulate subsets of biological activities of 1alpha,25(OH)(2)D(3) in osteoblasts.Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding.Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha.Primary Salivary Human Stem/Progenitor Cells Undergo Microenvironment-Driven Acinar-Like Differentiation in Hyaluronate Hydrogel Culture.Inflammatory breast cancer: a model for investigating cluster-based dissemination.Biofunctionalization of electrospun PCL-based scaffolds with perlecan domain IV peptide to create a 3-D pharmacokinetic cancer model.Transcriptional activation by NFκB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironmentHydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.Ribozyme knockdown functionally links a 1,25(OH)2D3 membrane binding protein (1,25D3-MARRS) and phosphate uptake in intestinal cells.Rapamycin selectively reduces the association of transcripts containing complex 5' UTRs with ribosomes in C4-2B prostate cancer cells.Deficiency in perlecan/HSPG2 during bone development enhances osteogenesis and decreases quality of adult bone in miceThree-dimensional in vitro tumor models for cancer research and drug evaluation.A promoter-level mammalian expression atlasDecidual heparanase activity is increased during pregnancy in the baboon (Papio anubis) and in in vitro decidualization of human stromal cells.Membrane receptors for vitamin D steroid hormones: potential new drug targets.Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?Steroid hormone interactions with target cells: cross talk between membrane and nuclear pathways.Evolution of the perlecan/HSPG2 gene and its activation in regenerating Nematostella vectensisA control engineering approach to understanding the TGF-β paradox in cancer.Ultrahigh-throughput Generation and Characterization of Cellular Aggregates in Laser-ablated Microwells of Poly(dimethylsiloxane).Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures.Heparan sulfate proteoglycans: key players in cartilage biology.Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroidsA 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior.Biomaterials-based strategies for salivary gland tissue regenerationSingle molecule force measurements of perlecan/HSPG2: A key component of the osteocyte pericellular matrix.Perlecan--a multifunctional extracellular proteoglycan scaffold.Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patientsRibozyme-mediated reduction of wild-type and mutant cartilage oligomeric matrix protein (COMP) mRNA and proteinDynamic interactions between L-type voltage-sensitive calcium channel Cav1.2 subunits and ahnak in osteoblastic cells.
P50
Q24642832-F928E4AB-35F5-4F7B-B1C0-18B7AB03BAA5Q24650523-F084F3BE-770C-451B-801B-18C496085D46Q24682147-B4CC5FAD-6F78-4935-A779-8C4401D8A511Q28206882-359DDC3A-6CC4-442C-B61E-D29F024B4F86Q28240927-28E8AA04-CA77-45F9-9619-B9F5EE36C0E4Q28251561-F82EAE26-1CC2-45E4-98EF-0F12DF7C8B15Q28574001-A59765AC-7B3E-4A5C-8483-F5931D127030Q30468502-D989E2C1-ED74-41CD-BE10-3D12B3E3C8ACQ31118703-572F372C-E120-4C75-9310-3CB1D2D8BEA3Q31943517-DFAF2D78-5AC1-4D06-9F7D-6076AA51844BQ33275800-3EAD66A0-527A-4F6B-9CD0-AE2101A669DBQ33344600-71F3A6A0-7866-4D1F-9D68-FDC8661BCC52Q33722110-28B40372-FC40-44A0-8EC2-1E839D67256BQ33767606-5A090456-D085-4781-B617-79DC07CA6430Q33872737-C5F85B0D-8CFC-4A74-9299-38159FF7713FQ33882116-C252B44B-C26D-4F27-A4B0-DD2DBF073828Q33894635-9ECC034A-941B-447C-AABE-778FE9C87700Q33905422-14C59A78-390A-471E-BA88-2B786D265095Q34033097-E3CE0E50-2513-4356-B19F-9F841D35070EQ34064383-749424FE-6180-429B-BC9C-E2F242BD9079Q34225333-8A4381AF-C1A0-4EC4-8330-343EAD8AD755Q34412203-C6227131-31A5-4215-8284-7F1DD604AAA1Q34711645-DF57442B-251F-4EE2-B4B9-D43E0CABE52CQ35045823-CC57F51D-52A0-42BC-BFBD-5983F569E08FQ35141115-B07FEC88-7872-4DFD-97BA-7C606AA1DEEBQ35554355-08C3F9A2-1089-4EFF-8571-09BAC78DD37AQ35602519-3FFC5944-ECE6-484E-9FD1-32F0C7B53958Q35954349-2848E5C8-BF3F-4972-BB58-1AAEE2B60CA0Q35964472-B824C808-D6FD-42C3-8155-5CE3AE60B871Q35985227-A0EF66C1-1D30-457E-B57E-F77A5720A782Q36098139-F1FB6CFB-8D28-4EC9-A5DF-6268A7043C04Q36303680-3E8D44D3-570A-4817-81EE-0D5A05CD7852Q36385066-2FB62312-731B-48B6-ADBD-E252E6F497E2Q36566641-72FDBDB0-5BC5-4FFD-9255-E159BB63422EQ36716864-1EB57765-3C34-4A97-908C-5BF81D872C47Q36730532-B7EF982C-AF15-4FC0-AEF9-7F1FD6359482Q36795158-778ECB9B-B741-42FF-9D44-242A84D3AD26Q36962989-54F37913-3CCD-440D-9501-CB84EE9CC920Q37142088-9422246C-B7D3-49FE-B514-451ACC61312AQ37190325-30815AD0-DA3A-4003-97E2-B38BF250362D
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-4526-3088
@en
name
Mary C Farach-Carson
@ast
Mary C Farach-Carson
@en
Mary C Farach-Carson
@es
Mary C Farach-Carson
@nl
type
label
Mary C Farach-Carson
@ast
Mary C Farach-Carson
@en
Mary C Farach-Carson
@es
Mary C Farach-Carson
@nl
altLabel
Mary Farach-Carson
@en
prefLabel
Mary C Farach-Carson
@ast
Mary C Farach-Carson
@en
Mary C Farach-Carson
@es
Mary C Farach-Carson
@nl
P106
P1153
7004445074
P2798
P31
P496
0000-0002-4526-3088